Proteome Systems and VRI BioMedical collaborate on point-of-care diagnostic for assessing fitness of elite athletes in Australia
Proteome Systems and VRI BioMedical have finalised a binding master development agreement on development of point-of-care diagnostics.
The first joint product under this agreement involves the development of a simple, quantitative test for assessing the immune system of elite athletes.
This programme will involve partnering with sporting bodies, including The Australian Institute of Sport, to evaluate the effectiveness and utility of the test.
VRI has developed the reagents for the tests which will be configured in Proteome Systems's Diagnostiq platform which is a proprietary diagnostic test platform that is fast, simple to use, reliable and quantitative, making it ideal for point-of-care applications.
VRI chief executive Peter French said that partnering with Proteome Systems would accelerate the commercialisation of the company's diagnostic products. "The immune status test will complement VRI's programme of development of probiotic products to boost the immune system. The result will be that we will have companion programs in both detection and treatment".
Proteome Systems's chief executive Keith Williams said that the immune status test will be the first product in the human health area using the Diagnostiq platform.
This follows on from our programme with C-Qentec in the agricultural biotechnology area.
